BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ludvigsson JF, Andersson M, Bengtsson J, Eberhardson M, Fagerberg UL, Grip O, Halfvarson J, Hjortswang H, Jäghult S, Karling P, Nordenvall C, Olén O, Olsson M, Rejler M, Strid H, Myrelid P. Swedish Inflammatory Bowel Disease Register (SWIBREG) - a nationwide quality register. Scand J Gastroenterol 2019;54:1089-101. [PMID: 31498717 DOI: 10.1080/00365521.2019.1660799] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Rundquist S, Sachs MC, Eriksson C, Olén O, Montgomery S, Halfvarson J; SWIBREG Study Group. Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers.Aliment Pharmacol Ther. 2021;53:471-483. [PMID: 33340426 DOI: 10.1111/apt.16193] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
2 Östlund I, Werner M, Karling P. Self-monitoring with home based fecal calprotectin is associated with increased medical treatment. A randomized controlled trial on patients with inflammatory bowel disease. Scand J Gastroenterol 2021;56:38-45. [PMID: 33284639 DOI: 10.1080/00365521.2020.1854342] [Reference Citation Analysis]
3 Mouratidou N, Malmborg P, Järås J, Sigurdsson V, Sandström O, Fagerberg UL, Bröms G, Ludvigsson JF, Olén O; SWIBREG Study Group. Identification of Childhood-Onset Inflammatory Bowel Disease in Swedish Healthcare Registers: A Validation Study. Clin Epidemiol 2022;14:591-600. [PMID: 35520278 DOI: 10.2147/CLEP.S358031] [Reference Citation Analysis]
4 Lundberg Båve A, Bergquist A, Bottai M, Warnqvist A, von Seth E, Nordenvall C. Increased risk of cancer in patients with primary sclerosing cholangitis. Hepatol Int 2021. [PMID: 34357546 DOI: 10.1007/s12072-021-10214-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Shrestha S, Olén O, Eriksson C, Everhov ÅH, Myrelid P, Visuri I, Ludvigsson JF, Schoultz I, Montgomery S, Sachs MC, Halfvarson J, Olsson M, Hjortswang H, Bengtsson J, Strid H, Andersson M, Jäghult S, Eberhardson M, Nordenvall C, Björk J, Fagerberg UL, Rejler M, Grip O, Karling P, Block M, Angenete E, Hellström PM, Gustavsson A; SWIBREG Study Group. The use of ICD codes to identify IBD subtypes and phenotypes of the Montreal classification in the Swedish National Patient Register. Scand J Gastroenterol 2020;55:430-5. [PMID: 32370571 DOI: 10.1080/00365521.2020.1740778] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
6 Davies J, Faiz OD, Brown SR. Patient and clinician national registry synergy to enhance quality improvement in United Kingdom IBD surgery - is there appetite? Colorectal Dis 2021;23:5-6. [PMID: 33501777 DOI: 10.1111/codi.15447] [Reference Citation Analysis]
7 Axelrad JE, Sachs MC, Ludvigsson JF, Olén O; SWIBREG Study Group. A Novel Method for Quantifying Intestinal Inflammatory Burden in Inflammatory Bowel Disease Using Register Data. Clin Epidemiol 2020;12:1059-72. [PMID: 33116900 DOI: 10.2147/CLEP.S265404] [Reference Citation Analysis]
8 Forss A, Clements M, Myrelid P, Strid H, Söderman C, Wagner A, Andersson D, Hjelm F, Olén O, Ludvigsson JF, Halfvarson J; PROSE SWIBREG study group. Prospective observational study on Stelara (ustekinumab) assessing effectiveness in Crohn's disease (PROSE): a 16-week follow-up. Scand J Gastroenterol 2021;56:680-6. [PMID: 33794731 DOI: 10.1080/00365521.2021.1906946] [Reference Citation Analysis]
9 Visuri I, Eriksson C, Olén O, Cao Y, Mårdberg E, Grip O, Gustavsson A, Hjortswang H, Karling P, Montgomery S, Myrelid P, Ludvigsson JF, Halfvarson J; SWIBREG study group. Predictors of drug survival: A cohort study comparing anti-tumour necrosis factor agents using the Swedish inflammatory bowel disease quality register. Aliment Pharmacol Ther 2021;54:931-43. [PMID: 34286871 DOI: 10.1111/apt.16525] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]